INS and type 2 diabetes mellitus: We demonstrate that an SGLT2 inhibitor significantly suppresses NLRP3 inflammasome activation and subsequent secretion of IL-1β in human macrophages, via increased serum BHB levels and decreased serum levels of insulin, among patients with T2D and CVD, regardless of glycemic control.